Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1998 1
2000 1
2003 2
2010 1
2011 2
2012 1
2014 1
2017 1
2018 2
2019 1
2020 1
2021 2
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. Among authors: dooms c. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L; CodeBreaK 200 Investigators. de Langen AJ, et al. Among authors: dooms c. Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7. Lancet. 2023. PMID: 36764316 Clinical Trial.
We randomly assigned (1:1) patients to oral sotorasib (960 mg once daily) or intravenous docetaxel (75 mg/m(2) once every 3 weeks) in an open-label manner using interactive response technology. ...
We randomly assigned (1:1) patients to oral sotorasib (960 mg once daily) or intravenous docetaxel (75 mg/m(2) once every 3 weeks) in …
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. Among authors: dooms c. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
Lung volume reduction in emphysema: a pragmatic prospective cohort study.
Dooms C, Blondeel A, Ceulemans LJ, Coolen J, Everaerts S, Demeyer H, Troosters T, Verleden G, Van Raemdonck D, Janssens W. Dooms C, et al. ERJ Open Res. 2021 May 31;7(2):00877-2020. doi: 10.1183/23120541.00877-2020. eCollection 2021 Apr. ERJ Open Res. 2021. PMID: 34084783 Free PMC article.
Between-group differences (meansem) for ELVR versus no-ELVR at 6-month follow-up were FEV(1) +0.210.05 L; RV -0.950.21 L; 6MWD 5817 m and SGRQ -185 points. At 6-month follow-up, within-group differences (meansem) for LVRS showed FEV(1) +0.270.06 L; RV -1.490.22 L and 6MWD …
Between-group differences (meansem) for ELVR versus no-ELVR at 6-month follow-up were FEV(1) +0.210.05 L; RV -0.950.21 L; 6MWD 5817 m …
Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.
Bauml JM, Li BT, Velcheti V, Govindan R, Curioni-Fontecedro A, Dooms C, Takahashi T, Duda AW, Odegaard JI, Cruz-Guilloty F, Jin L, Zhang Y, Anderson A, Skoulidis F. Bauml JM, et al. Among authors: dooms c. Lung Cancer. 2022 Apr;166:270-278. doi: 10.1016/j.lungcan.2021.10.007. Epub 2021 Oct 19. Lung Cancer. 2022. PMID: 34838325 Free PMC article.
Systematic and combined endosonographic staging of lung cancer (SCORE study).
Crombag LMM, Dooms C, Stigt JA, Tournoy KG, Schuurbiers OCJ, Ninaber MK, Buikhuisen WA, Hashemi SMS, Bonta PI, Korevaar DA, Annema JT. Crombag LMM, et al. Among authors: dooms c. Eur Respir J. 2019 Feb 7;53(2):1800800. doi: 10.1183/13993003.00800-2018. Print 2019 Feb. Eur Respir J. 2019. PMID: 30578389 Free article.
Endoscopic advanced imaging of the respiratory tract: exploring probe-based confocal laser endomicroscopy in emphysema.
Yserbyt J, Dooms C, Janssens W, Verleden GM. Yserbyt J, et al. Among authors: dooms c. Thorax. 2018 Feb;73(2):188-190. doi: 10.1136/thoraxjnl-2016-209746. Epub 2017 Apr 14. Thorax. 2018. PMID: 28411249
Morphometry shows that the median cross-sectional area of the alveolar openings at the level of the alveolar ducts is significantly larger in emphysema (7.210(4) m(2)) as compared with healthy subjects (5.210(4) m(2)) (p=0.0002). ...
Morphometry shows that the median cross-sectional area of the alveolar openings at the level of the alveolar ducts is significantly larger i …
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.
Vansteenkiste J, Vandebroek J, Nackaerts K, Dooms C, Galdermans D, Bosquée L, Delobbe A, Deschepper K, Van Kerckhoven W, Vandeurzen K, Deman R, D'Odemont JP, Siemons L, Van den Brande P, Dams N; Leuven Lung Cancer Group. Vansteenkiste J, et al. Among authors: dooms c. Lung Cancer. 2003 May;40(2):191-9. doi: 10.1016/s0169-5002(02)00515-9. Lung Cancer. 2003. PMID: 12711121 Review.
We now report the detailed individual symptom control analysis, and the influence of cisplatin-use, age, performance status (PS) and duration of treatment. PATIENTS AND METHODS: Patients received either GEM (1000 mg/m(2), days 1, 8 and 15) or cisplatin (100 mg/m(2), …
We now report the detailed individual symptom control analysis, and the influence of cisplatin-use, age, performance status (PS) and duratio …
21 results